news

Experimental gel promotes arteriovenous fistula (AVF) formation in rodents

The self-assembling, nanomatrix gel may represent the first effective therapy to promote healthy arteriovenous fistula (AVF) maturation in kidney disease patients.

Man's back with kidneys highlighted in orange

Researchers at the University of Alabama at Birmingham, US, and Endomimetics, a biotechnology company, have showed that an experimental gel can help create a fully developed arteriovenous fistula (AVF) in rodents, along with significantly improved vascular access. According to the team, the therapy could hold promise for kidney-dialysis patient care. 

NEWS: Lead compound for potential treatment of acute kidney injury identified

READ HERE

Most end-stage kidney disease patients are kept alive through chronic haemodialysis to remove waste products from their blood. This requires durable access to a blood vessel site where the dialysis machine can remove and return blood which is created when a surgeon attaches a vein to an artery in the patient. The pressure of the arterial blood forces the vein to expand. After this AVF develops and matures, that enlarged space becomes the lifeline for the haemodialysis patient.

However, up to 60 percent of AVFs fail to develop adequately, due to smooth muscle cell hyperplasia and inadequate expansion of the vein. The new gel could therefore represent the first effective therapy to promote healthy AVF maturation.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

The team began by demonstrating that nitric oxide plays an important regulatory role in AVF development. Mice that over-expressed endothelial nitric oxide synthase had reduced intimal hyperplasia development and vein narrowing in their AVFs, compared to control mice. The researchers reasoned that finding a way to release nitric oxide at a newly formed AVF might support development and maturation.

The researchers then developed a self-assembling, nanomatrix gel capable of releasing a burst of nitric oxide in the first 24 hours, followed by sustained release for four weeks. The study, published in Biomaterials, showed that when the gel was applied to a newly joined artery-vein meant to create an AVF in rats, the gel persisted at that site, and the rats showed a more than 70 percent reduction of intimal hyperplasia formation, as well as an improvement in vein diameter and a smoother blood flow, compared to controls.

“Therefore, direct application of the nitric oxide releasing nanomatrix gel to the AVF anastomosis immediately following AVF creation may enhance AVF development, thereby providing long-term and durable vascular access for haemodialysis,” the researchers concluded.

The team also explained that showing that the gel substantially increases the success rate of AVF development could result in dramatic improvement to the quality of life of patients, as well as a significant decrease in the cost of creating AVFs.

Leave a Reply

Your email address will not be published. Required fields are marked *